Pharmafile Logo
Pharmafocus logo
Advanced Search

haemophilia

Showing 15 posts of 53 posts found.

roche__tree

Roche’s haemophilia A drug shows meaningful bleed control in P3

December 7, 2017
Research and Development Roche, haemophilia, pharma

Roche has unveiled new Phase 3 data for its haemophilia A treatment Helimbra (emicizumab) in patients over 12 years of …

News
blood_bags

Contaminated blood inquiry to probe thousands of deaths

July 12, 2017
Medical Communications, Research and Development HCV, HIV, biotech, drugs, haemophilia, pharma, pharmaceutical

UK Government has announced that it will launch an inquiry to discover how 4,670 people were given blood infected by …

News
shire_image

Shire and Roche haemophilia spat spills into court

July 10, 2017
Sales and Marketing Roche, Shire, haemophilia

Roche released new scientific data at a conference in Berlin regarding its developmental drug in haemophilia, emicizumab, and Shire chose …

News
roche

Roche haemophilia therapy cuts bleed rate by 87%

June 26, 2017
Research and Development, Sales and Marketing Roche, haemophilia

Roche has revealed new data on its investigational haemophilia therapy ACE910 (emicizumab) which shows an 87% reduction in bleed rate …

News
blood-1813410_960_720

‘World Hemophilia Day’ marked by release of data

April 20, 2017
Medical Communications, Research and Development Roche, Shire, haemophilia

‘World Hemophilia Day’ occurred on 17 April and the day was marked by the release of data from two companies …

News
roche_close

Death in trial of Roche’s potential blockbuster haemophilia drug

February 24, 2017
Medical Communications, Research and Development Novo Nordisk, Roche, Shire, haemophilia

Roche has reported a death in the trial of its haemophilia treatment, emicizumab, that will only add to safety concerns …

News
blood-75302_640

Researchers develop capsule-based haemophilia treatment tech

November 30, 2016
Research and Development University of Texas, haemophilia

Researchers at the University of Texas have developed a new method for treating haemophilia B which utilises a biodegradable oral …

News

FDA approves Shire’s haemophilia A treatment system

August 1, 2016
Manufacturing and Production, Research and Development FDA, Shire, adynovate, baxject, haemophilia

Shire has announced that the Food and Drug Administration (FDA) has approved the baxject III reconstitution system for adynovate [antihemophilic …

News
gavel

Baxalta sues Chugai for haemophilia drug patent breach

May 11, 2016
Research and Development Baxalta, Chugai, breach, court, haemophilia, infringe, infringement, patent, sue, suing

Baxalta has taken Chugai Pharmaceuticals to the Tokyo district court, claiming that the Japanese company has infringed upon its patent …

News

Biogen to spin off its haemophilia business

May 4, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Biogen, Business, alprolix, eloctate, haemophilia, hemophilia, spin off, spin-off

Biogen (NASDAQ: BIIB) has announced plans to spin off its haemophilia business as an independent, publicly traded company. To be …

News
novo_corp_hq2

Novo unveils new research grant to mark World Haemophilia Day

April 18, 2016
Medical Communications, Research and Development, Sales and Marketing Novo Nordisk, grant, haemophilia, hero, world haemophilia day

Novo Nordisk has marked World Haemophilia Day 2016 with the announcement of a new research grant aimed at supporting and …

News
bayercross3

FDA approves Bayer haemophilia A drug Kovaltry

March 17, 2016
Research and Development, Sales and Marketing Bayer, FDA, approval, drug, drug approval, haemophilia, haemophilia a, kovaltry, viii compound

Bayer (ETR:BAYN) has received approval from the US Food and Drug Administration (FDA) for Kovaltry (octocog alfa), an unmodified, full-length …

News
csl_behring

FDA approves CSL Behring’s new haemophilia B treatment

March 7, 2016
Research and Development, Sales and Marketing CSL Behring, haemophilia

The US Food and Drug Administration (FDA) has approved CSL Behring’s Idelvion (Coagulation Factor IX (Recombinant)), a novel, long-acting albumin …

News
genzyme_logo

Genzyme opts into Alnylam’s Thrombosis program

October 2, 2015
Medical Communications, Research and Development Alnylam, Genzyme, Sanofi, haemophilia

Sanofi subsidiary Genzyme has elected to opt into Alnylam’s investigational ALN-AT3 hemophilia program for development and potential future commercialisation in …

News
Novo image

Novo Nordisk invests in haemophilia with Denmark facility

May 5, 2015
Manufacturing and Production, Sales and Marketing Novo Nordisk, diabetes, haemophilia, novoseven

Novo Nordisk is spending around $225 million on a new facility in Kalundborg, Denmark to produce active pharmaceutical ingredients for haemophilia …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025